文献速递肿瘤 PET/CT神经核医学

靶向MMP-14的双模态PET与荧光成像用于临床前胶质瘤模型

Targeting MMP-14 for dual PET and fluorescence imaging of glioma in preclinical models.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2019-11-26

本研究设计了一种含近红外荧光染料/淬灭剂对、PET放射性核素及MMP-14高亲和力基序的肽探针,仅在MMP-14切割后激活荧光信号,用于胶质瘤双模态成像。在体外和原位PDX胶质瘤小鼠模型中验证了MMP-14表达与活性、探针切割激活、生物分布及PET/NIRF信号相关性,证明该探针可实现胶质瘤PET/NIRF成像。

要点

  • MMP-14在胶质瘤中过表达而正常脑组织几乎不表达,可作为胶质瘤成像的生物标志物。
  • 新型MMP-14底物结合肽经MMP-14切割后激活NIRF信号,提高探针特异性和成像对比度。
  • 在原位PDX胶质瘤小鼠中,68Ga结合肽或64Cu底物结合肽PET/CT显示肿瘤摄取,且可被非标记肽阻断。

核心结论

  • 新型MMP-14底物结合肽在小鼠胶质瘤模型中实现了PET/NIRF双模态成像,值得在临床前模型中进一步开展图像引导切除术研究。

研究设计与样本

  • 临床前研究:设计含NIRF染料/淬灭剂对、PET放射性核素和MMP-14高亲和力基序的肽探针,在体外和原位PDX胶质瘤小鼠模型中进行验证。

主要发现

  • 具有MMP-14活性的胶质瘤细胞显示切割肽的NIRF信号激活和滞留。
  • 静脉注射肽后4小时,切除的PDX胶质瘤小鼠脑肿瘤与背景NIRF比值为7.6-11.1。
  • 静脉注射68Ga结合肽或64Cu底物结合肽后,PET/CT显示原位PDX肿瘤放射性定位,非标记结合肽阻断后肿瘤摄取显著降低(p < 0.05)。
  • 原位PDX肿瘤中PET与NIRF信号呈线性相关,免疫组化显示切除肿瘤中MMP-14表达与NIRF信号共定位。

关键数值与推荐

  • 肿瘤与背景NIRF比值为7.6-11.1(静脉注射肽后4小时,切除的PDX胶质瘤小鼠脑)。
  • 非标记结合肽阻断后肿瘤放射性肽摄取显著降低(p < 0.05)。

临床怎么用

  • 该探针有望用于胶质瘤的术前PET定位和术中NIRF荧光引导切除,但尚未在临床中验证。

局限性

  • 研究仅在小鼠胶质瘤模型中进行,尚未开展人体研究。
  • 未来需在临床前胶质瘤模型中开展图像引导切除术研究以进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: There is a clinical need for agents that target glioma cells for non-invasive and intraoperative imaging to guide therapeutic intervention and improve the prognosis of glioma. Matrix metalloproteinase (MMP)-14 is overexpressed in glioma with negligible expression in normal brain, presenting MMP-14 as an attractive biomarker for imaging glioma. In this study, we designed a peptide probe containing a near-infrared fluorescence (NIRF) dye/quencher pair, a positron emission tomography (PET) radionuclide, and a moiety with high affinity to MMP-14. This novel substrate-binding peptide allows dual modality imaging of glioma only after cleavage by MMP-14 to activate the quenched NIRF signal, enhancing probe specificity and imaging contrast. METHODS: MMP-14 expression and activity in human glioma tissues and cells were measured in vitro by immunofluorescence and gel zymography. Cleavage of the novel substrate and substrate-binding peptides by glioma cells in vitro and glioma xenograft tumors in vivo was determined by NIRF imaging. Biodistribution of the radiolabeled MMP-14-binding peptide or substrate-binding peptide was determined in mice bearing orthotopic patient-derived xenograft (PDX) glioma tumors by PET imaging. RESULTS: Glioma cells with MMP-14 activity showed activation and retention of NIRF signal from the cleaved peptides. Resected mouse brains with PDX glioma tumors showed tumor-to-background NIRF ratios of 7.6-11.1 at 4 h after i.v. injection of the peptides. PET/CT images showed localization of activity in orthotopic PDX tumors after i.v. injection of 68Ga-binding peptide or 64Cu-substrate-binding peptide; uptake of the radiolabeled peptides in tumors was significantly reduced (p < 0.05) by blocking with the non-labeled-binding peptide. PET and NIRF signals correlated linearly in the orthotopic PDX tumors. Immunohistochemistry showed co-localization of MMP-14 expression and NIRF signal in the resected tumors. CONCLUSIONS: The novel MMP-14 substrate-binding peptide enabled PET/NIRF imaging of glioma models in mice, warranting future image-guided resection studies with the probe in preclinical glioma models.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Kasten BB, Jiang K, Cole D, et al. Targeting MMP-14 for dual PET and fluorescence imaging of glioma in preclinical models. Eur J Nucl Med Mol Imaging. 2019. PMID: 31773232. doi:10.1007/s00259-019-04607-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。